Comparative effectiveness of high dose versus adjuvanted influenza vaccine
van Aalst, Robertus; Gravenstein, Stefan; Mor, Vincent; Mahmud, Salaheddin M; Wilschut, Jan; Postma, Maarten; Chit, Ayman
Published in:
Vaccine
DOI:
10.1016/j.vaccine.2019.09.105

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Version created as part of publication process; publisher's layout; not normally made publicly available

Publication date:
2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 06-01-2020
Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study

Robertus van Aalst a,b,*, Stefan Gravenstein c,d,e,f, Vincent Mor c,d, Salaheddin M. Mahmud g,h, Jan Wilschut i, Maarten Postma a,j,k, Ayman Chit b,l

a Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
b Vaccine Epidemiology and Modelling, Sanofi Pasteur, Swiftwater, PA, USA
c Brown University, School of Public Health, Dept. Health Services, Policy and Practice, USA
d Providence VA Medical Center, Center of Long-Term Services and Support, USA
e Center for Gerontology & Healthcare Research, Providence, RI, USA
f Warren Alpert Medical School of Brown University, Providence, RI, USA
g Department of Community Health Sciences, College of Medicine, University of Manitoba, Winnipeg, MB, Canada
h Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
i George & Fay Yee Center for Healthcare Innovation, University of Manitoba/Winnipeg Regional Health Authority, Winnipeg, MB, Canada
j Department of Economics, Econometrics & Finance, University of Groningen, Faculty of Economics & Business, Groningen, the Netherlands
k Unit of PharmacoTherapy–Epidemiology &–Economics (PTE2), University of Groningen, Department of Pharmacy, Groningen, the Netherlands
l Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada

ARTICLE INFO
Article history:
Received 25 June 2019
Received in revised form 26 September 2019
Accepted 30 September 2019
Available online xxxx

Keywords:
HD-IIV3
aIIV3
High-dose
Adjuvanted
Influenza vaccine
Comparative effectiveness
Relative vaccine effectiveness
rVE
Previous event rate ratio
PERR
Unmeasured confounding factors
Residual confounding

ABSTRACT

Background: Adults 65 years and older (seniors) experience more complications following influenza infection than younger adults. We estimated the relative vaccine effectiveness (rVE) of a trivalent high dose (HD-IIV3) versus an adjuvanted trivalent influenza vaccine (aIIV3) in seniors for respiratory-related hospitalizations.

Methods: We conducted a retrospective cohort study using claims data from Optum’s Clininformatics® Data Mart to compare outcome rates between seniors who received HD-IIV3 versus aIIV3 during the 2016/17 and 2017/18, predominantly A/H3N2 respiratory seasons. Rates were adjusted for demographic characteristics, comorbid conditions, previous influenza vaccination, and geography. We used the previous event rate ratio (PERR) approach to address bias by time-fixed unmeasured confounders.

Results: We identified 842,282 HD-IIV3 and 34,157 aIIV3 recipients for the 2016/17 season and 1,058,638 HD-IIV3 and 189,636 aIIV3 recipients for the 2017/18 season. The pooled rVE of HD-IIV3 versus aIIV3 for respiratory-related hospitalizations over both seasons was 12% (95% confidence interval: 3.3%–20%); 13% (6.4% to 23%) for the 2016/17 season and 12% (2.1%–21%) for the 2017/18 season.

Conclusions: Pooled over two predominantly A/H3N2 respiratory seasons, HD-IIV3 was associated with fewer respiratory hospital admissions than aIIV3 in senior members of large national managed health care company in the U.S.

Corresponding author at: Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA 18370, USA.
E-mail address: rob.vanaalst@sanofi.com (R. van Aalst).

1. Background

Adults 65 years and older (hereinafter referred to as seniors) are at greater risk for complications following influenza infection compared with younger adults, due in part to immunsenescence and increased comorbid conditions, leading to decreased vaccine efficacy and increased severity of influenza-related complications [1,2]. As a result, influenza-associated hospitalization and mortality rates are significantly higher in this age group [3–6]. In the 2017–18 respiratory season, seniors in the United States (U.S.) were estimated to have incurred over 650,000 influenza-associated hospitalizations and 65,000 influenza-associated deaths – 69% and 86% of the total number of influenza-associated hospitalizations and deaths, respectively [7]. Vaccination is the best preventive strategy against influenza infection [8]. As the U.S. population continues to age, it has become vitally important to use influenza vaccines that have demonstrated improved health outcomes in this high-risk population.
Standard dose (SD) inactivated influenza vaccines are derived from egg-grown viruses and contain 15 μg of hemagglutinin (HA) from each of three (trivalent, SD-IIV3, 45 μg HA total) or four (quadrivalent, SD-IIV4, 60 μg HA total) strains and are licensed in the U.S. for use in individuals 6 months of age or older. Due to immunosenescence, there is a need for vaccines that provide better protection than SD among seniors. Currently in the U.S., two influenza vaccines are licensed exclusively for use in seniors: an egg-grown trivalent high dose (HD-IIV3) influenza vaccine (Fluzone High-Dose, Sanofi Pasteur) and an egg-grown trivalent inactivated adjuvanted (allV3) influenza vaccine (Fluarq, Seqirus). HD-IIV3 aims to improve protection through quadrupling the dose per influenza strain from 15 μg HA to 60 μg HA (180 μg total) whereas allV3 is an SD-IIV3 vaccine to which an oil-in-water emulsion of squalene oil (MF59) is added.

In a randomized clinical trial (RCT), HD-IIV3 demonstrated superior efficacy (pre-specified superiority criterion: lower limit of the 2-sided 95% confidence interval (CI): >9.1%) in preventing clinically-relevant influenza disease, compared to SD-IIV3 [9]. In a meta-analysis of 7 studies that were conducted after licensure, HD-IIV3 was associated with less influenza-like illness compared to SD-IIV3 (rVE of 19.5%; 95% CI: 8.6–29.0%), with less hospitalized pneumonia (rVE of 24.3%, 95% CI: 13.9–33.4%) and with less hospitalizations for cardiorespiratory disease (rVE of 18.2%; 95% CI: 6.8–28.1%) [10]. Individual studies conducted among various populations during the 2011–12 through 2017–18 seasons have reported HD-IIV3 to be associated with reduced influenza-related complications compared to SD-IIV3 [11–18].

Although a few observational studies report that allV3 was associated with reduced influenza-related complications in seniors as compared to SD-IIV3 [18–20], no RCTs have evaluated the relative efficacy of allV3 against laboratory-confirmed influenza in seniors [21]. A meta-analysis, which included 39 trials comparing adults 60 years of age or older, who received either intradermal IIV3, HD-IIV3, or allV3, reported that both HD-IIV3 and allV3 demonstrated a significantly higher post-vaccination geometric mean titer to A(H3N2), as compared to SD-IIV3. Specifically, HD-IIV3 induced 82% higher titers to A(H3N2) as compared to SD-IIV3, which was statistically significantly higher than the 52% higher titers induced by allV3. In addition, HD-IIV3 elicited higher antibody titers in response to A(H1N1) and B/Victoria viruses, as compared to SD-IIV3 [22].

The recent utilization of both HD-IIV3 and allV3 in the U.S. enables the use of routinely collected data to assess the comparative effectiveness of the two vaccines. Recently, the first such observational study (Izurieta et al., J Infect Dis, 2018) reported that HD-IIV3 was associated with fewer influenza-related hospital encounters than allV3 (rVE of 7.7%, 95% CI: 5.1%, 10.2%) [18]. This study relied on exposure modeling methods (propensity score) that only adjust for measured confounding variables, but cannot account for unmeasured ones [23]. Frailty, for instance, is a confounder that may influence choice of vaccine, but may be hard to capture using claims data [15]. As such, there is a need for further comparative effectiveness research using methods that, to some extent, can address confounding by unmeasured variables. Here, we use the previous event rate ratio (PERR) approach, which adjusts for measured and unmeasured time-fixed confounders, to provide further evidence on the comparative effectiveness of HD-IIV3 versus allV3.

2. Methods

2.1. Design and data sources

We conducted a retrospective cohort study using claims data from Optum’s Clinformatics Data Mart (CDM) to compare outcome rates between recipients of HD-IIV3 and allV3 during two respiratory seasons: 2016/17 and 2017/18.

CDM is derived from a database of administrative health claims for members of a large national managed care company affiliated with Optum (hereinafter referred to as members). The database includes approximately 17–19 million annually covered members, for a total of over 60 million unique members over a 9 year period (1/2007 through 12/2018). CDM is statistically de-identified under the Expert Determination method consistent with HIPAA [24,25]. The administrative claims submitted for payment by providers and pharmacies are verified, adjudicated, adjusted, and de-identified prior to inclusion. CDM data comprises both commercial and Medicare Advantage health plan data. The population is geographically diverse, spanning all 50 states. In addition to medical claims and pharmacy claims, the data includes information on member eligibility and inpatient confinements.

2.2. Study population and influenza vaccination

The study population included all members aged 65 years and older at time of vaccination. Vaccinations received in a doctor’s office were identified by Current Procedural Terminology (CPT) codes (HD-IIV3 vaccine CPT code: 90662, allV3 vaccine CPT code: 90653) or National Drug Code (NDC, Supplemental Table 2). Vaccinations received in a community pharmacy were identified by brand names.

2.3. Study periods

Following prior work [26], we defined the start of the respiratory season as July 1 and the end as June 30 of the next calendar year. Within each respiratory season, we defined a baseline period starting on July 1 and ending on the day of vaccination. We used this period as an indicator for confounding, because here the vaccines will have no impact on the outcome rates: a treatment effect in this period could be an indicator for residual confounding [27]. Allowing for immunological response following vaccination, the observation period started two weeks after vaccination and ended at the end of the respiratory season on June 30. Here, outcome rates may be influenced by the vaccines. Baseline characteristics were observed during one year before vaccination.

2.4. Inclusion and exclusion criteria

To increase the probability of capturing a member’s baseline characteristics and outcomes, we included members with continuous enrollment starting at least one year before vaccination and ending not before the end of the respiratory season on June 30. If a member dies during this period, we counted their enrollment until the month of death. We applied two exclusion criteria. First, members for whom we found more than one vaccination record per respiratory season were excluded. Second, members with an observation period less than two weeks – due to late vaccination or death – were excluded. We relaxed these inclusion and exclusion criteria in a stability analysis [28].

2.5. Baseline characteristics

We classified members on demographic characteristics; month, region and point of vaccination (community pharmacy versus doctor’s office); influenza vaccination in the previous season; and by presence of certain health conditions (Table 1). We captured baseline characteristics during a period of one year before vaccination. We identified the 17 medical conditions used to calculate the Deyo-Charlson score by primary and secondary discharge diagnostic codes (International Classification of Diseases [ICD]-10 from
outpatient visits and hospital admissions. We deemed a condition present on the basis of a qualifying ICD code from a single hospital admission or two outpatient visits.

2.6. Outcomes

The primary outcome of the study was any hospitalization in which the patient record indicated a respiratory condition (ICD-10-CM: Jxx) as the principal discharge diagnosis [29]. The secondary outcome was any hospitalization for a cardio-respiratory condition (ICD-10-CM: Jxx – Jxx). We report hospitalizations for pneumonia, Supplemental Tables 1, 5 and 6).

We selected the PERR method because its performance to reduce bias caused by unmeasured confounding factors has been thoroughly described, both in simulation studies [30,32,34] and an empirical study comparing PERR estimates with RCTs [35]. The crude (unadjusted for measured baseline variables) relative vaccine effectiveness (rVE) is calculated as

\[
\text{rVE} = \left(1 - \frac{R_{b}}{R_{b}} \right) \times 100\%
\]  

We estimated crude rVEs by fitting a Poisson regression model with an interaction term between two variables, the period (observation versus baseline) and the treatment (HD-IIV3 versus allIV3). The regression model is shown below.

\[
\log (E(Y)) = \text{season} + \text{period} + \text{treatment} + \text{season} \times \text{period} + \text{season} \times \text{treatment} + \text{period} \times \text{treatment} + \text{season} \times \text{period} \times \text{treatment} + \text{log(daysatrisk)}
\]  

The coefficient of the interaction term period \times treatment is used to estimate \( \frac{R_{b}}{R_{b}} \), and thus the crude rVE. We adjusted the crude rVE for measured confounders by adding all baseline characteristics of Table 1 as covariates to the model above (model 2, except for Age Groups and the Deyo-Charlson Score, to prevent collinearity with Age and individual comorbid conditions). Pooled results over the two seasons were also calculated by removing

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Baseline characteristics of high dose (HD-IIV3) and adjuvanted influenza vaccine (allIV3) recipients.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Population</td>
<td>Season 2016/17</td>
</tr>
<tr>
<td></td>
<td>HD-IIV3</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>842,282</td>
</tr>
<tr>
<td>Female</td>
<td>490,969</td>
</tr>
<tr>
<td>Unknown</td>
<td>49</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>23,751</td>
</tr>
<tr>
<td>African American</td>
<td>54,599</td>
</tr>
<tr>
<td>Hispanic</td>
<td>61,328</td>
</tr>
<tr>
<td>White</td>
<td>569,019</td>
</tr>
<tr>
<td>Unknown Race</td>
<td>138,384</td>
</tr>
<tr>
<td>Age</td>
<td></td>
</tr>
<tr>
<td>65–69</td>
<td>189,369</td>
</tr>
<tr>
<td>70–74</td>
<td>234,809</td>
</tr>
<tr>
<td>75–79</td>
<td>175,214</td>
</tr>
<tr>
<td>80–84</td>
<td>125,263</td>
</tr>
<tr>
<td>85+</td>
<td>117,627</td>
</tr>
<tr>
<td>Age (mean, sd)</td>
<td>75.57</td>
</tr>
<tr>
<td>HHS Region</td>
<td></td>
</tr>
<tr>
<td>Region 1: CT, ME, MA, NH, RI, VT</td>
<td>31,004</td>
</tr>
<tr>
<td>Region 2: NJ, NY, PR, VI</td>
<td>62,302</td>
</tr>
<tr>
<td>Region 3: DE, DC, MD, PA, VA, WV</td>
<td>27,988</td>
</tr>
<tr>
<td>Region 4: AL, FL, GA, KY, MS, NC, SC, TN</td>
<td>210,553</td>
</tr>
<tr>
<td>Region 5: IL, IN, MI, MN, OH, WI</td>
<td>165,564</td>
</tr>
<tr>
<td>Region 6: AR, LA, NM, OK, TX</td>
<td>83,243</td>
</tr>
<tr>
<td>Region 7: IA, KS, MO, NE</td>
<td>38,421</td>
</tr>
<tr>
<td>Region 8: CO, MT, ND, SD, UT, WY</td>
<td>59,664</td>
</tr>
<tr>
<td>Region 9: AZ, CA, GA, HI, NV</td>
<td>122,521</td>
</tr>
<tr>
<td>Region 10: AK, ID, OR, WA</td>
<td>39,264</td>
</tr>
<tr>
<td>Unknown Region</td>
<td>1,758</td>
</tr>
</tbody>
</table>

(continued on next page)
the interaction term season × period × treatment. We used a robust variance estimator for each rVE, and after exponentiation, the delta-method to calculate 95% confidence intervals.

We compared baseline characteristics between HD-IIV3 and aIIV3 recipients using standardized mean differences. We adopted the rule that an absolute standardized mean difference smaller than 0.1 suggests no substantial difference between the compared groups [36].

2.8. Stability analyses

Supplemental Tables 7–15 catalog the various additional analyses we performed to evaluate the stability of our main results with slightly different study design choices [28]. Given the fact that the PERR method only adjusts for time-fixed unmeasured confounding factors, and the likelihood of potential design choice (baseline to observation period) dependent unmeasured confounders to be correlated with geographic location, we compared results from our primary analysis with results stratified by state, the smallest geographic area in our data set (Supplemental Tables 7 and 8). In addition, we compared results from the primary analysis with a matched cohort on state and both state and month of vaccination (Supplemental Table 9), both crude and adjusted for baseline characteristics (Supplemental Table 10). In addition to comparing the primary analysis to the matched cohorts, we also ran a primary analysis where we added state level characteristics (Supplemental Table 4) as covariates to the Poisson regression: our attempt to reduce unmeasured adjustments, stratification and matching to the 2017–18 season. Because of the small number of aIIV3 recipients in 2016–17, we limited all state level adjustments, stratification and matching to the 2017–18 season.

Given the fact that the PERR method uses longitudinal data, we evaluated if patient-level clustering influenced our main analyses by repeating them using generalized estimating equation methods with the independent (Supplemental Table 12) and autoregressive-1 (Supplemental Table 13) working correlation structure. Given the fact that Poisson regression assumes limited heterogeneity of the study population, we evaluated if overdispersion in the outcome data influenced our main analyses by fitting a negative binomial regression (Supplemental Table 14). Because temporal differences between vaccination date and peak of the circulating viral activity...
vary by geography, we evaluated if these differences were sufficiently adjusted for in our main analyses by repeating them after matching on vaccination month and region (Supplemental Table 14) [37]. Possible heterogeneity of insurance plans (e.g., different co-pays) can influence a member’s choice of one vaccine over the other. We evaluated if heterogeneity of insurance plans influenced our main analyses by adjusting for the 83 most common insurance plans: the most granular stratification with at least one member in each stratum during the two seasons (Supplemental Table 14). In the last stability analysis, we assessed the effects of relaxing the inclusion and exclusion criteria on the main results. Because we required continuous enrollment until the end of the observation period or death, whichever came first, we evaluated if dropping this complete case requirement influenced our main analysis. Instead, we required enrollment only to last until the start of the observation period with a minimum length of the observation period of one day (instead of 14 days). Missing outcome data – lost to follow-up – was addressed weighting complete cases with the inverse of a member’s propensity of having a complete case, using the baseline characteristics of Table 1 and insurance plan type all cases – complete and incomplete. In addition we only counted the first hospitalization. We censored person-time after the first hospitalization, death, or the end of the observation period, whichever occurred first (Supplemental Table 15).

3. Results

We identified 842,282 HD-IIV3 and 34,157 aIIV3 recipients for the 2016/17 season and 1,058,638 HD-IIV3 and 189,636 aIIV3 recipients for the 2017/18 season. Table 1 lists all baseline characteristics. Gender, race, age groups, number of all-cause hospitalizations and comorbid conditions were not substantially different (absolute SMD less than to 0.1) between HD-IIV3 and aIIV3 recipients. We did however observe substantial differences (absolute SMD greater than, or equal to 0.1) in a number of baseline characteristics. Some substantial differences were only observed in one season: these were in geographic region and month of vaccination. In 2016/17, Region 1 (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island and Maine) received substantially more allIIV3 vaccinations than HD-IIV3 vaccinations, while in 2017/18 the biggest difference was observed in Region 4 (Alabama, Florida, Georgia, Kentucky, Mississippi, North and South Carolina and Tennessee). In 2016/17, allIIV3 recipients received their vaccine, on average, 3 weeks later than HD-IIV3 recipients, but we didn’t observe a difference in 2017/18. Other baseline characteristics were substantially different in both seasons: the point of vaccination and the vaccination history. We observed that 52% of HD-IIV3 recipients received their vaccine in a doctor’s office, compared to 30% of allIIV3 recipients. In 2017/18, 62% of all HD-IIV3 recipients received HD-IIV3 in the previous season compared to 55% of all allIIV3 recipients. 6.3% of all allIIV3 recipients had received allIIV3 in the previous season compared to 1.6% of all HD-IIV3 recipients.

All imbalances in baseline characteristics were addressed by including the variables of Table 1 as covariates in the adjusted regression analysis.

During the baseline period, we observed statistically significant higher hospitalization rates for respiratory disease among members who would eventually receive HD-IIV3 (Table 2). Crude rate ratios (HD-IIV3 versus allIIV3) were 1.29 (95% CI: 1.03, 1.54) and 1.28 (95% CI: 1.16, 1.42) for the 2016/17 and 2017/18 seasons, respectively. During the observation period, however, the difference was less pronounced: 1.09 (95% CI: 0.68, 1.61) and 1.15 (0.93, 1.39) for the 2016/17 and 2017/18 seasons, respectively, resulting in a crude rVE of HD-IIV3 versus allIIV3 of 95% (95% CI: –4.3%, 34%) in 2016/17 and 11% (95% CI: 1.0%, 20%) in 2017/18.

After adjusting the respiratory hospitalization rates for baseline characteristics listed in Table 1, adjusted rate ratios (HD-IIV3 versus allIIV3) during the baseline period were 1.13 (95% CI: 0.91, 1.35) and 1.14 (95% CI: 1.03, 1.25) for the 2016/17 and 2017/18 seasons, respectively (Table 3), suggesting residual bias caused by unmeasured confounding factors. During the observation period the adjusted rates were 0.98 (95% CI: 0.61, 1.44) and 1.01 (0.81, 1.22) for the 2016/17 and 2017/18 seasons, respectively. We estimated an adjusted rVE of HD-IIV3 versus allIIV3 of 13% (95% CI: –6.4%, 32%) in 2016/17 and 12% (95% CI: 2.1%, 21%) in 2017/18 (Supplemental Fig. 1). Pooling the data from both season resulted in an adjusted summary rVE of 12% (3.3%, 20%), Table 4.

For our secondary outcome, hospitalizations for cardio-respiratory disease, the crude rVE of HD-IIV3 versus allIIV3 was 14% (95% CI: 4.0%, 25%) in 2016/17 and 5% (95% CI: –0.1%, 10%) in 2017/18. After adjusting these hospitalization rates for baseline characteristics listed in Table 1, the adjusted rVE was 13% (95% CI: 2.3%, 23%) in 2016/17 and 6% (95% CI: 0.6%, 11%) in 2017/18. Pooling the data from both seasons resulted in an adjusted summary rVE of 7% (2.3%, 12%). For our test-negative control, hospitalizations for UTI, the adjusted rVE was –20% (95% CI: –95%, 18%) in 2016/17 and 3% (95% CI: –12%, 17%) in 2017/18. Pooling the data from both season resulted in an adjusted summary rVE of –1% (–15%, 13%), suggesting no treatment effect.

### Table 2
Crude rates, rate ratios (RR) and relative vaccine effectiveness (rVE) with 95% confidence intervals for allIIV3 and HD-IIV3 (HD) recipients in the baseline and observation periods for respiratory seasons 2016–17 and 2017–18.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Baseline period</th>
<th>Observation period</th>
<th>rVE*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>Rate</td>
<td>RR</td>
</tr>
<tr>
<td></td>
<td>Rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Season 2016-17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory disease</td>
<td>allIIV3 121</td>
<td>101 (81, 120)</td>
<td>1.29 (1.03, 1.54)</td>
</tr>
<tr>
<td></td>
<td>HD 3,193</td>
<td>129 (84, 185)</td>
<td>1.29 (1.03, 1.54)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>allIIV3 482</td>
<td>400 (359, 461)</td>
<td>1.25 (1.12, 1.38)</td>
</tr>
<tr>
<td></td>
<td>HD 12,361</td>
<td>500 (402, 609)</td>
<td>1.25 (1.12, 1.38)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>allIIV3 70</td>
<td>58 (41, 73)</td>
<td>1.12 (0.82, 1.42)</td>
</tr>
<tr>
<td></td>
<td>HD 1,610</td>
<td>65 (35, 104)</td>
<td>1.12 (0.82, 1.42)</td>
</tr>
<tr>
<td>Season 2017-18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory disease</td>
<td>allIIV3 622</td>
<td>109 (99, 119)</td>
<td>1.28 (1.16, 1.41)</td>
</tr>
<tr>
<td></td>
<td>HD 4,390</td>
<td>140 (115, 167)</td>
<td>1.28 (1.16, 1.41)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>allIIV3 2,572</td>
<td>451 (431, 471)</td>
<td>1.18 (1.12, 1.23)</td>
</tr>
<tr>
<td></td>
<td>HD 16,639</td>
<td>531 (483, 581)</td>
<td>1.18 (1.12, 1.23)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>allIIV3 332</td>
<td>58 (51, 65)</td>
<td>1.12 (0.97, 1.26)</td>
</tr>
<tr>
<td></td>
<td>HD 2,036</td>
<td>65 (50, 82)</td>
<td>1.12 (0.97, 1.26)</td>
</tr>
</tbody>
</table>

Rates are in number of outcomes (No) per 10,000 person-years. Hospitalizations were classified using the principal discharge diagnosis. Confidence intervals were calculated using a robust variance estimator. We applied the Previous Event Rate Ratio (PERR) to address unmeasured confounders by including an interaction term of Period (observation versus baseline period) and treatment (HD-IIV3 versus allIIV3).

Please cite this article as: R. van Aalst, S. Gravenstein, V. Mor et al., Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study, Vaccine, https://doi.org/10.1016/j.vaccine.2019.09.105.
Table 3
Rate ratios (RR) and relative vaccine effectiveness (rVE) with 95% confidence intervals for aIIV3 and HD-IIV3 recipients in the baseline and observation periods for respiratory seasons 2016–17 and 2017–18, crude and adjusted for baseline characteristics.

<table>
<thead>
<tr>
<th>Hospitizations</th>
<th>Baseline period</th>
<th>Observation period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RR, crude</td>
<td>RR, adjusted</td>
</tr>
<tr>
<td></td>
<td>RR, crude</td>
<td>RR, adjusted</td>
</tr>
<tr>
<td><strong>Season 2016–17</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory disease</td>
<td>1.29 (1.03, 1.54)</td>
<td>1.13 (0.91, 1.35)</td>
</tr>
<tr>
<td>Cardio-respiratory disease</td>
<td>1.25 (1.12, 1.38)</td>
<td>1.11 (1.00, 1.23)</td>
</tr>
<tr>
<td>Urinary Tract Infection</td>
<td>1.12 (0.82, 1.42)</td>
<td>0.98 (0.72, 1.24)</td>
</tr>
<tr>
<td><strong>Season 2017–18</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory disease</td>
<td>1.28 (1.16, 1.41)</td>
<td>1.14 (1.03, 1.25)</td>
</tr>
<tr>
<td>Cardio-respiratory disease</td>
<td>1.18 (1.12, 1.23)</td>
<td>1.07 (1.02, 1.12)</td>
</tr>
<tr>
<td>Urinary Tract Infection</td>
<td>1.12 (0.97, 1.26)</td>
<td>0.91 (0.78, 1.08)</td>
</tr>
</tbody>
</table>

Rates are in number of outcomes (No) per 10,000 person-years. Hospitalizations were classified using the principal discharge diagnosis. Confidence intervals were calculated using a robust variance estimator. We applied the Previous Event Rate Ratio (PERR) to address unmeasured confounders by including an interaction term of Period (observation versus baseline period) and treatment (HD-IIV3 versus aIIV3). The Rate ratios and PERR were adjusted for observed confounding factors by including all the baseline characteristics of Table 1 as covariates, except for Age Groups and the Deyo-Charlson Score, to prevent collinearity with Age and individual comorbid conditions. Hospitalizations were classified using the principal discharge diagnosis.

Table 4
Relative vaccine effectiveness (rVE) with 95% confidence intervals of high dose (HD-IIV3) versus adjuvanted influenza vaccine (aIIV3) for respiratory seasons 2016–17, 2017–18 and the two seasons combined (summary rVE), adjusted for baseline characteristics.

<table>
<thead>
<tr>
<th>Hospitizations</th>
<th>2016–17 season</th>
<th>2017–18 season</th>
<th>Summary rVE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory disease</td>
<td>13% (-6.3%, 32%)</td>
<td>12% (2.1%, 21%)</td>
<td>12% (3.3%, 20%)</td>
</tr>
<tr>
<td>Cardio-respiratory disease</td>
<td>13% (2.3%, 23%)</td>
<td>6% (0.6%, 11%)</td>
<td>7.0% (2.3%, 12%)</td>
</tr>
<tr>
<td>Urinary Tract Infection</td>
<td>-20% (-59%, 19%)</td>
<td>2.5% (-12%, 17%)</td>
<td>-0.7% (-14%, 13%)</td>
</tr>
</tbody>
</table>

Confidence intervals were calculated using a robust variance estimator. We applied the Previous Event Rate Ratio (PERR) to address unmeasured confounders by including an interaction term of Period (observation versus baseline period) and treatment (HD-IIV3 versus aIIV3). The PERR was adjusted for observed confounding factors by including all the baseline characteristics of Table 1 as covariates, except for Age Groups and the Deyo-Charlson Score, to prevent collinearity with Age and individual comorbid conditions. Hospitalizations were classified using the principal discharge diagnosis.

3.1. Stability analyses

We observed low numbers of hospitalizations for respiratory disease for the 2017–18 season when stratified by state, limiting the conclusions than can be drawn from these results (Supplemental Tables 7 and 8). Two matched cohort analyses for the 2017–18 season: one on state only, and another on both state and month of vaccination, resulted in higher rVEs compared to the primary analysis of season 2017–18 (Supplemental Tables 9 and 10). The higher rVEs were mainly driven by higher rate ratios in the baseline period, suggesting increased residual confounding. Pooled results from the matched analysis over two seasons on vaccination month and region to adjust for temporal and geographic heterogeneity were similar to the results of the main analysis (Supplemental Table 14). Results of a stability analysis where we added state level characteristics as covariates to the Poisson regression of the primary analysis, as well as all other stability analyses, were similar to the results of the main analysis (Supplemental Tables 11–13 and 15).

4. Discussion

We analyzed 1,900,920 HD-IIV3 and 223,793 aIIV3 recipients aged 65 years and older in senior members of large national managed care company in the U.S. Pooled over two seasons, HD-IIV3 was associated with lower hospitalization rates for respiratory as well as cardio–respiratory disease compared to aIIV3. More specifically, the adjusted rVE of HD-IIV3 versus aIIV3 for hospitalizations with underlying respiratory disease was 12% (95% CI: 3.3, 20%). The adjusted rVE of HD-IIV3 versus aIIV3 for hospitalizations with underlying cardio–respiratory disease was 7% (95% CI: 2.3, 12%).

Our findings are consistent with data from the U.S. Centers for Disease Control and Prevention. Indeed, Izurieta and colleagues reported that HD-IIV3 was associated with lower hospitalization rates for probable influenza (hospitalization with an administrative ICD-10 code of 489 on any position on the claim) when compared to aIIV3, with an rVE of 7.7% (95% CI: 5.1%, 10.2%) in the 2017–18 season [18]. Similarly, we also estimated that HD-IIV3 was associated with reduced hospitalizations for respiratory disease. Of note, our outcome definition was different than Izurieta et al. in that it captured, in our primary analysis, all respiratory related hospital admissions during the influenza season. The specificity and sensitivity of our outcome and the one reported by Izurieta et al. are therefore different. Further, Izurieta at al. used an inverse probability of treatment weighting (IPTW) method to balance differences between cohorts. However, propensity score methods adjust only for measured confounders, not unmeasured confounders. If HD-IIV3 recipients were frailer than aIIV3 recipients, residual confounding from unmeasured variables would bias the relative treatment effect to the null. For these two reasons, it is challenging to quantitatively compare the rVEs between our study and Izurieta et al.; however, it is noteworthy that directionally HD-IIV3 is in both studies associated with reduced hospitalization rates compared to aIIV3.

Our study has multiple strengths. First, we used a method that adjusts for confounding from unmeasured variables through the use of the PERR method and measured variables through regression. The adjusted rate ratios in the baseline period (Table 3) suggest residual bias caused by unmeasured confounding factors [27]. Because of this observation, we feel it appropriate to use the PERR method. When comparing the effectiveness of IIV3-HD and IIV3-SD in the VHA population using the PERR method, Young-Xu and colleagues observed a similar pattern: the relative risk in the observa...
tion period was 1.16, suggesting IV3-SD to be more effective than IIV3-HD [15]. The relative risk in the baseline period, however, was 1.54 suggesting a strong selection bias. Applying PERR resulted in a relative risk of 0.75 – more in line with a wide body of evidence consisting of both randomized and observational studies [10]. It might be helpful to keep in mind that PERR is in essence a form of difference-in-differences – a method widely used in the field of economics to adjust for unmeasured confounding factors [33].

Second, we included in our study a negative control outcome of UTI admissions where we expected no association between vaccination status and the outcome. Reassuringly we did not observe a treatment effect UTI in season 2017–18 and the pooled analysis. This allows us to assume that the PERR model was not misspecified. Third, by requiring an observation period of at least two weeks we created a minimal time window to observe outcomes. As a result, we excluded members with a high propensity of dying at time of vaccination, a confounding variable that is otherwise hard to measure [38], and members who received vaccination after June 16. Because we realize that any time subjects are excluded from an analysis, other biases might be introduced inadvertently, we dropped this requirement in a stability analysis. Last, we extensively tested the validity of our assumptions and design choices by including various stability analyses, which did not alter our findings in a clinically significant way (Supplemental Tables 7–15).

Our study also has limitations. First, the heterogeneity in influenza viral circulation and intensity from year to year limits the generalizability of the study results as the two seasons of our study where predominantly H3N2 with limited H1N1 or circulation. In 2016–17, public health laboratories typed 76% of all positive influenza tests to be of H3N2, 2% were H1N1, and 22% were type B [39]. In 2017–18, the distribution was 60% H3N2, 11% H1N1, and 29% type B [2]. Additionally, because our study allV3 cohort in 2016–17 was over fivefold smaller than in 2017–18, our combined results were heavily influenced by the second season, in which a recent study demonstrated reduced protection from antibodies induced by vaccination to egg-propagated A/H3N2 compared with antibodies to the circulating a/H3N2 virus [40]. The impact on the current analysis, if any, is unclear because both HD-IIV3 and allV3 are egg-based vaccines. Of note, the 2016–17 season was characterized by a good match between circulating strains and vaccine antigens. The rVE for respiratory-related hospitalizations did not significantly decrease from season 2016–17 to season 2017–18. A possible explanation could be that egg-adaptation reduces overall vaccine effectiveness equally in both HD-IIV3 and allV3. Second, although PERR is an adaptation of the well-established difference-in-differences method, it is unable to adjust for unobserved time-varying (from baseline to observation period) confounders. In addition, it assumes that outcome rate changes from baseline to observation period in the allV3 cohort are similar to those in the HD-IIV3 cohort, if they had received allV3 instead. This common ratio assumption is comparable with the parallel trend assumption of the difference-in-differences method [33]. Although this assumption cannot be tested, baseline and observation periods are relatively close together, which reduces the chance of violating this assumption for confounding factors like frailty, hospital/provider access issues and propensity to hospitalize. PERR cannot adjust for confounding factors that vary from baseline to observation period, like local influenza vaccination rates (impacting herd immunity), and local prevalence of influenza – if left unmeasured. In a stability analysis, we did measure these local confounding factors – the length of the peak influenza season and influenza vaccination rates in the general population – on the state level for season 2017–18 (Supplemental Table 4), the most geographically granular data available to us. When adding these confounding factors to the covariates of the primary analysis (Supplemental Table 10), we saw a slightly higher rVE for hospitalizations for respiratory disease in 2017–18: from 12% (95% CI: 2.1%, 21%) to 14% (95% CI: 3.4%, 24%). Matching on state resulted in even higher rVEs, but mainly driven by higher rate ratios in the baseline period, suggesting increased residual confounding (Supplemental Table 10). Our data did not allow for capturing of geographic heterogeneity of potentially time-varying confounding factors on a more granular level than the state level. Potential variation of weather, viral activity and vaccination rates within a state (e.g., at the county or postal code level) may confound our results. We could have further reduced confounding by indication had we excluded providers offering both vaccines at the same location at the same time. Although provider level details prevented us from excluding these providers, doing so might have come at the cost of increasing geographic heterogeneity of other confounding factors: when comparing HD-IIV3 with SD-IIV3, Izurieta and colleagues matched on provider to reduce this type of confounding [41].

Third, the size of the cohort in 2016–17 did not enable us to extract statistically significant inferences specific to that season. Notably, the rVE for respiratory-related hospitalization in that first season was 13% (95% CI: −6.4%, 32%) and the rVE against our negative control, where we estimated the rVE against UTI, was erratic and non-statistically significant.

As the use of the HD-IIV3 and allV3 grows, future effectiveness studies should attempt to examine more specific outcomes such as hospital admissions with a principal discharge code for pneumonia/influenza and hospital admissions following a positive influenza test. Our study was not able to study the former due to small cohort size and low incidence rates, and the latter due to absence of laboratory results data. However, these specific end-points will take public health closer to understanding the causal link between these vaccines and preventing adverse health outcomes following an influenza infection.

5. Conclusion

Pooled over two predominantly A/H3N2 respiratory seasons, HD-IIV3 was associated with fewer respiratory- and cardio-respiratory-related hospital admissions than allV3 in senior members of large national managed care company in the U.S.

Funding statement

This study was funded by a research grant from Sanofi Pasteur, Inc., Swiftwater, PA, USA.

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RVA and AC are employees of Sanofi Pasteur.

SG has received research support (investigator initiated grant funding) from Seqirus and Sanofi, consulting for Sanofi, consulting for Merck, speaker fees for Seqirus.

SMM has received research funding from Assurex, GSK, Merck, Pfizer, Roche and Sanofi, and is/was a member of advisory boards for GSK and Sanofi.

VM has received research funding from Sanof Pasteur, is Chair of the Independent Quality Committee at HCR Manor Care, and Chair of the Scientific Advisory Board and consultant at NaviHealth, Inc., as well as former Director of PointRight, Inc., where he holds less than 1% equity.

JW and MP declare that they have no known competing interests.
Acknowledgments

We thank Issa Dahabreh, MD, ScD, for assistance with stability analyses and comments that greatly improved the manuscript.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2019.09.105.

References


Please cite this article as: R. van Aalst, S. Gravenstein, V. Mor et al., Comparative effectiveness of high dose versus unadjuvanted influenza vaccine: A retrospective cohort study, Vaccine, https://doi.org/10.1016/j.vaccine.2019.09.105.